Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

13. november 2026 oppdatert av: Viking Therapeutics, Inc.

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.

Studietype

Intervensjonell

Registrering (Antatt)

560

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Arizona
      • Tucson, Arizona, Forente stater, 85741
        • Rekruttering
        • Viking Clinical Site #2020
        • Ta kontakt med:
          • Telefonnummer: 520-333-4515
    • California
      • Lake Forest, California, Forente stater, 92630
        • Rekruttering
        • Viking Clinical Site #2015
        • Ta kontakt med:
          • Telefonnummer: 714-550-9990
    • Florida
      • Ocoee, Florida, Forente stater, 34761
        • Rekruttering
        • Viking Clinical Site #2059
        • Ta kontakt med:
          • Telefonnummer: 407-654-2724
    • Georgia
      • Atlanta, Georgia, Forente stater, 30329
        • Rekruttering
        • Viking Clinical Site #2013
        • Ta kontakt med:
          • Telefonnummer: 404-920-6201
    • Indiana
      • Evansville, Indiana, Forente stater, 47714
        • Rekruttering
        • Viking Clinical Site #2001
        • Ta kontakt med:
          • Telefonnummer: 812-477-2760
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Viking Clinical Site #2046
        • Ta kontakt med:
          • Telefonnummer: 504-336-2667
      • Valparaiso, Indiana, Forente stater, 46383
        • Rekruttering
        • Viking Clinical Site #2009
        • Ta kontakt med:
          • Telefonnummer: 219-464-8302
    • Minnesota
      • Richfield, Minnesota, Forente stater, 55423
        • Rekruttering
        • Viking Clinical Site #2004
        • Ta kontakt med:
          • Telefonnummer: 952-922-7000
    • Mississippi
      • Jackson, Mississippi, Forente stater, 39206
        • Rekruttering
        • Viking Clinical Site #2029
        • Ta kontakt med:
          • Telefonnummer: 770-330-4157
    • Missouri
      • Springfield, Missouri, Forente stater, 65807
        • Rekruttering
        • Viking Clinical Site #2028
        • Ta kontakt med:
          • Telefonnummer: 504-338-0917
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87107
        • Rekruttering
        • Viking Clinical Site #2052
        • Ta kontakt med:
          • Telefonnummer: 505-243-1627
    • New York
      • Binghamton, New York, Forente stater, 13905
        • Rekruttering
        • Viking Clinical Site #2039
        • Ta kontakt med:
          • Telefonnummer: 607-800-5777
    • Oregon
      • Medford, Oregon, Forente stater, 97504
        • Rekruttering
        • Viking Clinical Site #2023
        • Ta kontakt med:
          • Telefonnummer: 541-858-1018
    • Rhode Island
      • East Greenwich, Rhode Island, Forente stater, 02818
        • Rekruttering
        • Viking Clinical Site #2002
        • Ta kontakt med:
          • Telefonnummer: 401-739-9350
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29407
        • Rekruttering
        • Viking Clinical Site #2044
        • Ta kontakt med:
          • Telefonnummer: 843-432-2477
    • Tennessee
      • Hendersonville, Tennessee, Forente stater, 37075
        • Rekruttering
        • Viking Clinical Site #2030
        • Ta kontakt med:
          • Telefonnummer: 504-339-0917
    • Texas
      • Abilene, Texas, Forente stater, 79606
        • Rekruttering
        • Viking Clinical Site #2031
        • Ta kontakt med:
          • Telefonnummer: 325-400-1150
    • Washington
      • Seattle, Washington, Forente stater, 98105
        • Rekruttering
        • Viking Clinical Site #2011
        • Ta kontakt med:
          • Telefonnummer: 206-536-3030
      • Spokane, Washington, Forente stater, 99218
        • Rekruttering
        • Viking Clinical Site #2042
        • Ta kontakt med:
          • Telefonnummer: 509-505-6227

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 years of age at the time of signing the informed consent.
  2. Body mass index (BMI) ≥ 27 kg/m2
  3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.

Exclusion Criteria:

  1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation

  2. Self-reported body weight change of 5% or more within 3 months of screening

  3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)

  4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)

  5. Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)

  6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening

    • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.

  7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization

  8. Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.

  9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)

  10. History of acute or chronic pancreatitis

  11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo Assignment

Placebo comparator orally once daily

Placebo comparator administered orally once daily

Eksperimentell: Active Assignment (Dose 1)

VK2735 Dose level 1 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Eksperimentell: Active Assignment (Dose 2)

VK2735 Dose level 2 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Eksperimentell: Active Assignment (Dose 3)

VK2735 Dose level 3 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Tidsramme: 68 weeks

To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68

68 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. oktober 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

5. oktober 2026

Først innsendt som oppfylte QC-kriteriene

5. oktober 2026

Først lagt ut (Faktiske)

9. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere